Table 2.

Hematological characteristic of MPN.

N° patient	MPN	Mutation	Diagnosis /pregnancya	Thrombosis score (IPSET)	Hematological treatment during pregnancy	CHR or MMR
1	ET	JAK2V617F	Missed during pregnancy n°1 Given before pregnancy n°2	HIGH	Interferon during pregnancy n°2	Yes (n°2)
2	ET	JAK2V617F	During	LOW	Interferon during all pregancies	No
3	ET	Triple neg	During	LOW	None	No
4	ET	Triple neg	During	LOW	None	No
5	ET	Triple neg	Missed	LOW	None	No
6	ET	JAK2V617F	Missed	LOW	None	No
7	ET	JAK2V617F	During	LOW	None	No
8	ET	JAK2V617F	Missed during pregnancy n°12 Before for pregnancy n°13	LOW	Interferon during pregnancy n°13	Yes
9	ET	JAK2V617F	Before	LOW	Interferon	No
10	ET	Non JAK2V617F	During	LOW	None	No
11	CML	BCR-ABL1	Before	NA	Interferon	No
12	CML	BCR-ABL1	During	NA	None	No
13	CML	BCR-ABL1	During	NA	None	Yes

^aMissed: The diagnosis was missed during pregnancy.

During: MPN was diagnosed during pregnancy; Before: MPN had already been diagnosed; MPN : myeloproliferative neoplasm; ET: essential thrombocytosis; CML: chronic myelogenous leukemia; IPSET: international prognostic score of thrombosis (11);CHR: in case of ET, complete hematological remission; MMR in case of CML: major molecular response. Triple neg : « triple negative » i.e. no mutation found. NonJAK2V617F: means patient was tested only for JAK2V61F and not for CAL-RX and MPL, NA: Not applicable.